Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980394 | 0.88 | KDM2B (0.55) | HSP90AB1HRH3SLC6A7KDM2BKCNH2 | |
| SCHEMBL4977010 | 0.88 | HSP90AB1 (0.51) | HSP90AB1HRH3HSD11B1SLC6A7SCN9A | |
| SCHEMBL4977142 | 0.88 | KDM4E (0.45) | HRH3 | |
| SCHEMBL4976783 | 0.88 | HSP90AB1 (0.49) | HSP90AB1HRH3KDM2BKCNH2 | |
| SCHEMBL4976016 | 0.87 | PANK3 (0.45) | HRH3KCNH2 | |
| SCHEMBL4977103 | 0.87 | HSP90AB1 (0.63) | HSP90AB1HRH3SLC6A7KCNH2 | |
| SCHEMBL4976292 | 0.87 | HPGD (0.48) | HSP90AB1HRH3KDM2BKCNH2 | |
| SCHEMBL4976026 | 0.87 | HRH3 (0.54) | HSP90AB1HRH3SLC6A7KDM2BKCNH2 | |
| SCHEMBL4977984 | 0.86 | HSP90AB1 (0.47) | HSP90AB1HRH3KDM2BKCNH2 | |
| SCHEMBL4980657 | 0.86 | MAPT (0.39) | HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885HRH3 1/4885PDE4B 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.